Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial

S Verma, DL Bhatt, SC Bain, JB Buse, JFE Mann… - Circulation, 2018 - Am Heart Assoc
CORRESPONDENCE years), and more patients were male (68.8% versus 67.9%), were
current or previous smokers (67.1% versus 60.1%), had an estimated glomerular filtration …

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.

S Verma, DL Bhatt, SC Bain, JB Buse, JFE Mann… - Circulation, 2018 - europepmc.org
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and
Polyvascular Disease: Results of the LEADER Trial. - Abstract - Europe PMC Sign in | Create an …

[PDF][PDF] Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease

S Verma, DL Bhatt - scholar.archive.org
Results of the LEADER Trial years), and more patients were male (68.8% versus 67.9%),
were current or previous smokers (67.1% versus 60.1%), had an estimated glomerular …

Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease results of the LEADER trial

S Verma, DL Bhatt, SC Bain, JB Buse, JFE Mann… - Circulation, 2018 - cdr.lib.unc.edu
The presence of polyvascular disease, defined as atherosclerosis involving> 1 distinct
vascular territory, is a strong, independent predictor of cardiovascular events. In the …

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

S Verma, DL Bhatt, SC Bain, JB Buse, JFE Mann… - 2018 - pubmed.ncbi.nlm.nih.gov
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and
Polyvascular Disease: Results of the LEADER Trial Effect of Liraglutide on Cardiovascular …